Imricor (IMR) March Quarterly Report: Progressing Towards FDA Registration Strategy

2021-04-29 05:29:42 (AET) by Ring Zhang   405

Imricor Medical Systems (ASX: IMR) released its quarterly report for the three months ended 31 March 2021, providing investors with business updates associated with its leading MRI-guided cardiac ablation products, as well as financial and operational performance.

Imricor Medical Systems (ASX: IMR), an ASX-listed medical devices producer, released its quarterly report for the three months ended 31 March 2021, providing investors with business update associated with its leading MRI-guided cardiac ablation products, and financial and operational performance.

The company reported cash receipts from customer of US$0.234 million and held US$20.68 million at period end. Estimated quarters of funding available at the same spending level would be 5.1 quarters.

As most countries in Europe reinitiated COVID-19 measures in response to the new wave of outbreak, Imricor confirmed that it has slowed down its new iCMR Lab roll-out plan. Moreover, the company’s contracted partners, including Leipzig Heart Centre and Maastricht University Medical Centre, have both temporarily halted procedures again due to the latest lockdown measures undertaken in Germany and Netherlands.

The company expects the measures in Germany will remain until June this year, while the Netherlands will start to ease restrictions next week. Notwithstanding these restrictions, Imricor is working closely with contracted sites to progress installation, training, and the commencement of operations as soon as allowed.
Currently, Imricor has 9 contracted sites and revealed that the signing of new agreements will recommence in the second quarter and accelerate in the second half of FY21.

In addition, the company is advancing the implementation of FDA strategy for its MRI-guided cardiac ablation products. Following the third pre-submission meeting with the US FDA, the company is confident in the study design of the clinical program, which is scheduled to commence in July this year.

In Australia, Imricor has appointed a local specialist Regional Health Care Group (RHCG) to facilitate TGA approval. As part of the service agreement, RHCG will be the exclusive distributor of Imricor’s consumable products in Australia and New Zealand and a non-exclusive distributor of Imricor’s capital equipment.

Expanding indications and opportunities beyond cardiac ablation has been a priority of the company. Imricor is currently researching and developing steerable sheaths and transseptal needles which, in the future, will enable access to the left side of the heart via the intra-atrial septum, for some more complex procedures. It is anticipated that these products will be ready for clinical trial during 2021.

In the meantime, the development program of Imricor’s diagnostic catheter is progressing well, aiming for commercial releases in late 2021 or early 2022.




版权所有,转载需注明出处:61 澳洲财经资讯


61 澳洲财经资讯邮件订阅服务,每日为您推荐最新澳洲财经资讯


维州金矿商DTM发出季度报告,旗舰Granite Flat项目第二拨勘探进行中

维州金矿勘探商Dart Mining NL (ASX:DTM) 今日公布截至2021年6月30日的季度报告。在该季度,包括金刚石钻探计划、反循环钻探计划和广泛的地球物理调查在内的勘探活动继续在Granite Flat快速进行。到目前为止,团队从采集的数据中得到极大鼓舞,并急切地等待着地球物理调查的解释。地面数据采集预计将于8月中旬结束。



磁共振引导心脏消融产品的全球领导者Imricor Medical Systems (ASX:IMR) 今日发布其截至2021年6月30日的季度现金流报告并提供财务和运营业绩的季度更新。季度内,该公司新增一个新站点——Helios Hospital Berlin-Buch。公司表示,虽然其分销管道仍然强劲,但由于冠状病毒病 (COVID-19) 带来的长期影响,以及6月和7月的接种率低于预期,新iCMR站点的合同签署进度比预期要慢。


可视化心脏消融设备公司Imricor Medical Systems,Inc.( ASX:IMR)宣布,已与德国柏林布赫Helios综合性医院(Helios Hospital Berlin-Buch)签署协议,成为第十个建立iCMR(介入性心脏磁共振成像)实验室的临床站点,将采用Imricor的产品在由MRI引导的环境下进行可视化的心脏消融手术。


医疗器械开发商Imricor Medical Systems, Inc.(ASX:IMR) 今日发出公告,称拓展取得重要的里程碑——其开发的Advantage-磁共振电生理记录仪/刺激器系统 (记录仪/刺激器) 系统获得了澳大利亚药监局TGA的批准。TGA目前也在对该公司配套的Vision-MR消融导管进行审查。